youtube_live
Q1 2026 earnings • in 4 days
See detailschevron_right
ZYME:NASDAQ
Zymeworks Inc
US$ २६.६१
arrow_downward
-३.३८%(-०.९३) 1D
US$ २६.६१
०.००% (०.००)
bedtimeAfter hours
Closed: मे १, १६:००:०० GMT-४ · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ZYME...
Open
US$ २७.५४
High
US$ २७.५४
Low
US$ २६.६१
Mkt. cap
१.९६ अरब
Avg. vol.
६.३७ लाख
Volume
३.७० लाख
52-wk high
US$ २८.४९
52-wk low
US$ १०.८६
EPS
-US$ १.०८
Beta
१.२०
Shares outstanding
७.३८ करोड
No. of employees
२६४
News stories
From sources across the web
Profile
Zymeworks Inc. is a publicly held biotechnology company based in Vancouver,
British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year. In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million. This was the largest Canadian biotech IPO in more than a decade. By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange.
In May 2019, Zymeworks announced that GSK has expanded its 2016 licensing and collaboration agreement for the research, development and commercialization of bispecific antibodies across multiple disease areas. The extended agreement has meant that GSK can have access to Zymeworks' heavy-light chain pairing technology, which enables the development of bispecific and multifunctional therapeutics. Wikipedia
About Zymeworks Inc
CEOKenneth Galbraith
Employees२६४
Founded२००३
HeadquartersMiddletown, डेलावेयर, संयुक्त राज्य अमेरिका
Sector-
Websitezymeworks.com
AI content may include mistakes. Learn more